Director & CEO
Dr. Volker Gerdts received a DVM in 1994 from Hanover Veterinary School and a German PhD equivalent from the Federal Research Institute for Animal Health, Island of Riems and Hanover Veterinary School, Germany, in 1997. A postdoctoral fellowship, funded by the German Research Council, was spent from 1998-2000 at VIDO-InterVac in the area of vaccine discovery and mucosal immunology. In 2002 Dr. Gerdts joined VIDO-InterVac as a Research Scientist. He was appointed Associate Director of Research in 2007, and became the Director and CEO in 2019.
Dr. Gerdts research interests are in the area of neonatal vaccines for both humans and animals, mucosal immunology, and vaccine delivery and formulation. Current research projects are focused on vaccine development for Porcine Reproductive and Respiratory Syndrome Virus, adjuvants, porcine immunology and the use of pigs as model for humans, immune modulation and regulation of mucosal immune responses.
- Neonatal vaccines for humans and animals
- Mucosal immunology
- Vaccine delivery and formulation
- African Swine Fever vaccine development
- Chlamydia trachomatis and Neisseria gonorrhoeae
- Development of a vaccine for contagious bovine pleuropneumonia
- Development of novel combination adjuvants
- Mycobacterial Pathogenesis and Tuberculosis Research Program
- Pertussis – development of a neonatal pertussis vaccine
- Pathogenesis for Porcine Reproductive and Respiratory Syndrome
- Pathogenesis of congenital Zika virus infection and sequelae in offspring
- Vaccine development for bacterial diseases of pigs
- Vaccine development for Porcine Epidemic Diarrhea